No evidence for BRAF-V600E mutations in gastroeosophageal tumors

• Verfasst von: Preusser, Matthias [VerfasserIn]
• Verfasst von: Bergmeister-Berghoff, Anna Sophie [VerfasserIn]
• Verfasst von: Capper, David [VerfasserIn]
• Verfasst von: Deimling, Andreas von [VerfasserIn]
• Verfasst von: Maroske, Florian [VerfasserIn]
• Verfasst von: Brodowicz, Thomas [VerfasserIn]
• Verfasst von: Hejna, Michael [VerfasserIn]
• Verfasst von: Birner, Peter [VerfasserIn]
• Verfasst von: Schoppmann, Sebastian F. [VerfasserIn]
• Titel: No evidence for BRAF-V600E mutations in gastroeosophageal tumors
• Titelzusatz: results from a high-throughput analysis of 534 cases using a mutation-specific antibody
• Verf.angabe: Matthias Preusser, Anna S. Berghoff, David Capper, Andreas von Deimling, Florian Maroske, Thomas Brodowicz, Michael Hejna, Peter Birner, Sebastian F. Schoppmann
• Jahr: 2013
• Umfang: 5 S.
• Fussnoten: Gesehen am 08.12.2021
• Titel Quelle: Enthalten in: Applied immunohistochemistry & molecular morphology
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1999
• Jahr Quelle: 2013
• Band/Heft Quelle: 21(2013), 5, Seite 426-430
• ISSN Quelle: 1533-4058
• DOI: doi:10.1097/PAI.0b013e31827ce693
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1780701128

Abstract

Background: BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds. Little data on the prevalence of BRAF-V600E mutations in tumors of the upper gastrointestinal tract are available. Materials and Methods: We constructed tissue microarrays of formalin-fixed and paraffin-embedded specimens of 534 gastroesophageal tumors (119 squamous cell cancers and 72 adenocarcinomas of the esophagus, 63 cancers of the gastroesophageal junction/cardia, 199 gastric cancers of the corpus or antrum, 81 gastric gastrointestinal stromal tumors) and performed anti-BRAF-V600E immunostaining using the mutation-specific antibody VE1. As control tissue we used 3 melanoma cases with confirmed BRAF-V600E mutation and distinct VE1 immunostaining. Results: None of the gastroesophageal tumor cases showed a positive immunostaining signal. Conclusions: BRAF-V600E mutation is not a relevant oncogenic driver in gastroesophageal tumors. Immunohistochemical analysis using mutation-specific antibodies on tissue microarrays is a feasible, time-efficient and cost-efficient approach to high-throughput screening for specific mutations in large tumor series.